Stock analysts expect ResMed Inc. (NYSE:RMD – Get Rating) to post earnings per share of $1.49 for the current fiscal quarter, according to Zacks Investment Research. Three analysts provided earnings estimates for ResMed, with the highest EPS estimate of $1.57 and the lowest estimate of $1.39. ResMed reported earnings of $1.35 per share in the same quarter last year, which would indicate a positive growth rate of 10.4% year over year. The company is expected to release its next quarterly results on Monday, January 1.
According to Zacks, analysts expect ResMed to report annual earnings of $5.73 per share for the current fiscal year, with EPS estimates ranging from $5.63 to $5.86. For next year, analysts expect the company to report earnings of $6.64 per share, with EPS estimates ranging from $6.41 to $6.89. Zacks EPS averages are an average average based on a survey of sell-side research companies that track ResMed.
ResMed (NYSE:RMD – Get Rating) last announced its quarterly results on Thursday, April 28. The medical equipment supplier reported earnings per share of $1.32 for the quarter, missing analyst consensus estimates of $1.44 per ($0.12). ResMed had a net margin of 22.02% and a return on equity of 26.91%. The company posted revenue of $864.50 million in the quarter, compared to $900.03 million expected by analysts. During the same period last year, the company made earnings per share of $1.30. ResMed’s revenue increased 12.4% year over year.
A number of equity research analysts have recently commented on the stock. Wolfe Research assumed coverage of ResMed shares in a report on Tuesday, April 5. They issued an “outperform” rating and a target price of $280.00 for the company. StockNews.com upgraded ResMed’s shares from a “buy” rating to a “hold” rating in a Monday, May 2 report. Finally, Royal Bank of Canada upgraded ResMed’s shares from an “sector performance” rating to an “outperform” rating and increased its target price for the company from $233.00 to $244.00 in a report released Monday. Six investment analysts gave the stock a hold rating and nine gave the company a buy rating. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $267.44.
In other news, insider David Pendarvis sold 1,545 ResMed shares in a trade that took place on Tuesday, May 3. The shares were sold at an average price of $200.00, for a total value of $309,000.00. Following the transaction, the insider now directly owns 109,858 shares of the company, valued at $21,971,600. The transaction was disclosed in a legal filing with the SEC, accessible via this hyperlink. Additionally, CEO Michael J. Farrell sold 5,675 ResMed shares in a trade that took place on Tuesday, March 15. The stock was sold at an average price of $242.37, for a total transaction of $1,375,449.75. The disclosure of this sale can be found here. During the last quarter, insiders sold 41,115 shares of the company worth $9,434,328. 1.42% of the shares are currently held by insiders.
Several institutional investors have recently changed their stake in the company. Comprehensive Financial Consultants Institutional Inc. acquired a new stake in ResMed stock in Q4 worth $25,000. Amplius Wealth Advisors LLC acquired a new equity stake in ResMed in Q4 worth $26,000. CVA Family Office LLC acquired a new equity stake in ResMed in Q4 valued at $31,000. GHP Investment Advisors Inc. acquired a new equity stake in ResMed in Q1 worth $33,000. Finally, Capital Advisors Ltd. LLC acquired a new equity stake in ResMed in Q4 valued at $39,000. Institutional investors and hedge funds hold 65.24% of the company’s shares.
NYSE:RMD shares traded down $2.23 on Wednesday, hitting $212.27. The company’s stock had a trading volume of 339,259 shares, compared to an average volume of 586,206. The stock’s 50-day moving average is $216.65 and its two-hundred-day moving average is 236. $.55. ResMed has a 52-week minimum of $189.40 and a 52-week maximum of $301.34. The company has a debt ratio of 0.20, a current ratio of 2.55 and a quick ratio of 1.56. The stock has a market capitalization of $31.05 billion, a P/E ratio of 39.98, a PEG ratio of 2.34 and a beta of 0.45.
The company also recently declared a quarterly dividend, which will be paid on Thursday, June 16. Shareholders of record on Thursday, May 12 will receive a dividend of $0.42. The ex-dividend date is Wednesday, May 11. This represents a dividend of $1.68 on an annualized basis and a dividend yield of 0.79%. ResMed’s payout ratio is currently 31.64%.
About ResMed (Get an evaluation)
ResMed Inc develops, manufactures, distributes and markets cloud-based medical devices and software applications for healthcare markets. The Company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies for application in medical and consumer products, ventilator devices, diagnostic products, mask systems for hospital and home use. , helmets and other accessories, dental appliances and the cloud. software-based IT solutions to manage patient outcomes, as well as to deliver customer and business processes.
Get a Free Copy of Zacks Research Report on ResMed (RMD)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
Get news and reviews for ResMed Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for ResMed and related companies with MarketBeat.com’s free daily email newsletter.